Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Anemia 2Thrombocytosis 1Primary Myelofibrosis 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 36fludarabine phosphate 32Tacrolimus 28Busulfan 24Peripheral Blood Stem Cell Transplantation 23Mycophenolic Acid 20Whole-Body Irradiation 19Antilymphocyte Serum 18Methotrexate 16fludarabine 14ruxolitinib 13Melphalan 12Cyclosporine 12thymoglobulin 8Stem Cell Transplantation 8Radiotherapy 8Methylprednisolone 8Sirolimus 6Prednisone 6Cord Blood Stem Cell Transplantation 6Specimen Handling 5Filgrastim 5Etoposide 5Alemtuzumab 5merphos 4itacitinib 4Imatinib Mesylate 4INCB039110 4Hematopoietic Stem Cell Transplantation 4Cytarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Primary Myelofibrosis × luspatercept × Clear all
NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Celgene

Phase 2 Completed
95 enrolled 32 charts
Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡